Pharmacy Department, Hospital Clínica Bíblica, San José, 10104, Costa Rica.
Costa Rican Social Security System, San José, 10103, Costa Rica.
BMC Public Health. 2024 Nov 18;24(1):3205. doi: 10.1186/s12889-024-20670-y.
Antimicrobial resistance is a significant global health threat. Therefore, robust surveillance systems for antimicrobial consumption (AMC) are essential to develop public health strategies. However, Latin American countries, including Costa Rica, face challenges in regularly reporting AMC data. This study aims to estimate and analyse the overall AMC in Costa Rica for 2019.
This study is a national-level, retrospective, observational, and descriptive analysis of AMC in Costa Rica from 1 January to 31 December 2019. The study followed the World Health Organization (WHO) guidelines for the Surveillance of National AMC. The Anatomical Therapeutic Chemical (ATC) / Defined Daily Doses (DDD) system was used to analyse types of antimicrobials and DDD per 1000 inhabitants per day (DID). Antimicrobial dispensation data from the Costa Rican Social Security Fund (CCSS) represented the public sector, while the private sector data was sourced from IQVIA. The analysis included data from both inpatient and outpatient sectors.
A total AMC of 14.32 DID, of which 12.75 DID was within the public sector and 4.12 DID was within the private sector. Penicillins had the highest consumption nationally and in the public sector, while macrolides and lincosamides predominate in the private sector. According to the WHO-AWaRe (Access-Watch-Reserve) classification, antibiotics predominantly consumed nationally (74.7%) and in the public (83.0%) sectors are categorized under Access, whereas the private (61.0%) sector predominates the Watch category.
This study illustrates the importance of enhancing AMC surveillance by integrating data from both the public and private sectors. The findings indicate an excessive use of "Watch" antimicrobials in the private sector. To address this issue, all sectors and regulatory authorities must play an active and supportive role, in the development of effective, multisectoral policies. The methodology employed in this study is applicable to other Latin American countries, and therefore should be utilized for future analysis AMC in this region.
抗菌药物耐药性是一个重大的全球健康威胁。因此,建立强大的抗菌药物消费监测系统对于制定公共卫生策略至关重要。然而,包括哥斯达黎加在内的拉丁美洲国家在定期报告抗菌药物消费数据方面面临挑战。本研究旨在估计和分析 2019 年哥斯达黎加的总体抗菌药物消费情况。
这是一项针对 2019 年 1 月 1 日至 12 月 31 日期间哥斯达黎加抗菌药物消费的全国性、回顾性、观察性和描述性分析。该研究遵循世界卫生组织(WHO)关于国家抗菌药物监测的指南。采用解剖治疗化学(ATC)/限定日剂量(DDD)系统分析各种抗菌药物和每 1000 居民每日 DDD(DID)。哥斯达黎加社会保障基金(CCSS)的抗菌药物配药数据代表公共部门,而私营部门的数据则来自 IQVIA。该分析包括住院和门诊部门的数据。
总抗菌药物消费为 14.32 DID,其中 12.75 DID 来自公共部门,4.12 DID 来自私营部门。青霉素在全国范围内和公共部门的消费最高,而大环内酯类和林可酰胺类在私营部门占主导地位。根据世卫组织-AWaRe(准入-观察-储备)分类,全国范围内(74.7%)和公共部门(83.0%)主要消费的抗生素属于准入类别,而私营部门(61.0%)主要消费的抗生素属于观察类别。
本研究通过整合公共和私营部门的数据,说明了加强抗菌药物监测的重要性。研究结果表明,私营部门过度使用“观察”类抗生素。为了解决这个问题,所有部门和监管机构都必须在制定有效、多部门政策方面发挥积极和支持的作用。本研究采用的方法适用于其他拉丁美洲国家,因此应在该地区未来的抗菌药物消费分析中加以利用。